Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.
In addition to dopaminergic neuron loss, it is clear that Parkinson disease includes other pathological changes, including loss of additional neuronal populations. As a means of addressing multiple pathological changes with a single therapeutically-relevant approach, we employed delayed transplantation of a unique class of astrocytes, GDAs(BMP), that are generated in vitro by directed differentiation of glial precursors. GDAs(BMP) produce multiple agents of interest as treatments for PD and other neurodegenerative disorders, including BDNF, GDNF, neurturin and IGF1. GDAs(BMP) also exhibit increased levels of antioxidant pathway components, including levels of NADPH and glutathione. Delayed GDA(BMP) transplantation into the 6-hydroxydopamine lesioned rat striatum restored tyrosine hydroxylase expression and promoted behavioral recovery. GDA(BMP) transplantation also rescued pathological changes not prevented in other studies, such as the rescue of parvalbumin(+) GABAergic interneurons. Consistent with expression of the synaptic modulatory proteins thrombospondin-1 and 2 by GDAs(BMP), increased expression of the synaptic protein synaptophysin was also observed. Thus, GDAs(BMP) offer a multimodal support cell therapy that provides multiple benefits without requiring prior genetic manipulation.
Department for Biomedical Genetics, University of Rochester, Rochester, NY, USA.
Christoph
C
Proschel
Jennifer L
JL
Stripay
Chung-Hsuan
CH
Shih
Joshua C
JC
Munger
Mark D
MD
Noble
D000818:Animals; D001253:Astrocytes / Q000166:cytology / Q000637:transplantation*; D064987:Cell- and Tissue-Based Therapy; D006801:Humans; D008297:Male; D009457:Neuroglia / Q000166:cytology / Q000637:transplantation; D010300:Parkinson Disease / Q000628:therapy*; D051381:Rats; D011916:Rats, Inbred F344